IKA vs Mira — how do they compare? IKA trades at Rp45.54 (market cap Rp136,33M, Rp3,86M 24h volume), while Mira trades at Rp700.16 (market cap Rp226,43M, Rp101,47M 24h volume). The key difference: Mira is the larger of the two by market cap, and Mira's supply is capped (321,5M / 1B MIRA (33%)) while IKA's keeps growing. Which is the better fit depends on your goals — on Pluang, investors hold IKA for 3 Days and Mira for 22 Days on average.
| IKA | MIRA | |
|---|---|---|
Market Cap | Rp136,33M | Rp226,43M |
Volume (24h) | Rp3,86M | Rp101,47M |
Circulating Supply | 3B IKA | 321,5M / 1B MIRA (33%) |
Typical Hold Time | 3 Days | 22 Days |
Signals from Pluang's Aura AI — not financial advice
IKA trades at Rp46.73 with a market cap of Rp141.55M, showing neutral technical signals across moving averages and oscillators. The token currently sits between support at Rp43 and resistance at Rp49, indicating consolidation. With a short average hold time of 3 days, traders appear to be taking quick positions rather than long-term holding. No recent protocol updates or ecosystem developments have been reported for this digital asset.
Overall outlook remains neutral with limited trading activity and minimal fundamental catalysts. Key opportunities include potential breakout above Rp49 resistance, while major risks include low liquidity and the token's small market cap making it vulnerable to volatility. Investors should monitor for any upcoming protocol developments or exchange listings that could drive momentum.
MIRA token trades at Rp724 with bearish technical signals as moving averages indicate strong selling pressure. The token shows neutral oscillators but faces resistance at Rp726-758 levels. With 33% circulating supply and 22-day average hold time, market participation remains limited. Recent ecosystem developments show progress in pharmaceutical research applications, though direct token utility updates are scarce.
Overall outlook remains cautious due to technical bearishness and limited trading volume. Key opportunity lies in potential protocol adoption from pharmaceutical research partnerships. Major risks include low liquidity, high volatility, and regulatory uncertainty surrounding crypto-pharma intersections. Investors should monitor exchange listings and token utility expansion.
What Pluang investors did over the last 30 days
Ika is a decentralized network enabling secure, native cross-chain interoperability through advanced cryptography. It allows smart contracts to manage assets across multiple blockchains without relying on bridges or wrapped tokens. Using 2PC-MPC cryptography, Ika provides zero-trust asset control across chains like Bitcoin and Ethereum. Its dWallet primitive enables programmable, consent-based signing, and it is built on Sui for high-speed, scalable transactions.
Read more on IKA →Mira is a decentralized verification network that enables autonomous AI by eliminating human oversight. Using consensus-based verification across multiple AI models, Mira delivers mathematically verifiable and trustless results in real time. This ensures accuracy and reliability for critical fields like healthcare, finance, and law—transforming AI from a supervised tool into truly independent intelligence.
Read more on MIRA →